Snow Software Introduces New Global Partner Program to Drive Exponential Growth in Channel Ecosystem
1.2.2023 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today announced a new global partner program designed to enable partners to support customers as they face complex market challenges around managing cost and mitigating risk, while delivering value more efficiently and effectively with Snow. The new program aims to drive exponential growth in the Snow channel ecosystem, creating new opportunities for partners to tap into an estimated and growing $11.5 billion Technology Intelligence market.
Developed in collaboration with its current channel ecosystem, the new Snow partner program includes better support for multiple business models of partners, encouraging the creation of value-added services and driving tangible customer success by leveraging Snow technology. The program includes more partner incentives and rewards than the current program, while streamlining collaboration with Snow to better deliver value to shared customers.
“Today’s economic climate demands more from every organization’s IT technology environment, which means that our partners have a greater responsibility to provide visibility, governance and optimization services for their customers,” said Vinod Chumber, Vice President of Ecosystem Sales at Snow. “In order to ensure our partners can deliver excellent outcomes, it was essential to create a new program that better enabled them with the right resources, education and solutions to succeed. As a partner-centric organization, we believe that our new program combined with our Snow Atlas platform is a powerful combination to address the turbulent market customers and partners face today. The new program is just the beginning as we continue to invest in our partners and create a rich ecosystem enabled to take advantage of the vision for Technology Intelligence.”
Creating transparency with the market, the partner portal will feature real-time dashboards featuring each partner’s strong record of success and specializations to arm customers with insight on the best partners suited to their needs. The new framework will remove channel conflicts, empowering partners to build new, value-add services and work closely with the Snow wider teams to drive customer success. Additional new program benefits include:
- Sales rewards and points system to recognize the investment that individuals within the partner organization are making;
- Self-service capabilities to create new operational efficiencies within the partner portal;
- Business development funds to market and promote partner sales offerings built on top of Snow technology;
- Shadowing programs to drive customer success and adoption of Snow best practices and certification opportunities;
- Free access to Snow e-learning to empower partners with the latest knowledge on the Snow product and solution portfolio;
- Snow Champion Program to recognize and reward individuals for their contribution to the Snow community; and
- Ongoing recognition and rewards opportunities including annual partner awards to celebrate the success, rewards for joint customer success stories and more.
“Our clients need powerful solutions and tools to deliver tangible business value, reduce overall IT costs and mitigate risks,” said Shadi Khoshab, Global Director, ITAM & Software Sourcing Services at SoftwareOne. “By enhancing and innovating its partner program, Snow is demonstrating its commitment to our strategic relationship and helping to drive our joint business forward, empowering our clients with invaluable, actionable insights that underpins successful digital transformation.”
In addition to the overall program, Snow is committed to releasing ongoing product capabilities specifically aimed at enabling its partner community. Most recently, Snow introduced two new Snow Atlas capabilities for partners to better support their customers with improved collaboration features. Customers can now give partners direct access to their Snow Atlas platform, allowing partners to manage customer environments in the cloud. In addition, partners can now create agent packages with a self-service tool in Snow Atlas without engaging Snow Support, making the end-to-end delivery more efficient.
The new Snow partner program will be available for all partners later this year. For more information about the Snow partner ecosystem or to become a Snow partner, please visit: https://www.snowsoftware.com/global-partner-program/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005359/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Champlin
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
